HomeQuestion

Would you consider ivosidenib for a patient with metastatic cholangiocarcinoma and an IDH1 mutation following progression on gem/cis and FOLFOX?

2

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

When treating with SBRT and immunotherapy for unresectable HCC, how do you sequence the treatment?

In pts with HCC who initially achieved a good response on durvalumab/tremelimumab , but later lost it, would you consider rechallenging with tremelimumab ?

How do you counsel patients on imaging findings after liver SBRT for HCC, particularly with regard to expectations on timing to tumor resolution?

How long would you continue atezolizumab/bevacizumab in a patient with HCC who is having a prolonged response with stable disease?

Which patients, if any, do you revert back to ultrasound screening for HCC after prior diagnosis/definitive treatment of HCC?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.